Comparing Relay Therapeutics (NASDAQ:RLAY) and Nuvation Bio (NYSE:NUVB)

Nuvation Bio (NYSE:NUVB – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares Nuvation Bio and Relay Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvation Bio $201.73 million 6.99 -$204.63 million ($0.40) -9.99
Relay Therapeutics $10.35 million 386.20 -$276.48 million ($1.51) -11.98

Nuvation Bio has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvation Bio and Relay Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuvation Bio -67.38% -45.69% -18.54%
Relay Therapeutics N/A -40.25% -36.82%

Institutional & Insider Ownership

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Nuvation Bio has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nuvation Bio and Relay Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio 1 2 9 0 2.67
Relay Therapeutics 1 1 11 1 2.86

Nuvation Bio presently has a consensus price target of $12.89, suggesting a potential upside of 222.63%. Relay Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 49.25%. Given Nuvation Bio’s higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Relay Therapeutics.

Summary

Relay Therapeutics beats Nuvation Bio on 8 of the 15 factors compared between the two stocks.

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.